E3 ubiquitin ligases as molecular targets in human oral cancers

Current Cancer Drug Targets

Volumn 16, Issue 2, 2016, Pages 130-135

  Masumoto, Kazuma ^a   Kitagawa, Masatoshi ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemical inhibitor; E3 ligase; Oral cancer; P27Kip1; Skp2; Smurf1; Ubiquitin proteasome system; WWP

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1B; HERMES ANTIGEN; PIRH2 PROTEIN; PROTEIN INHIBITOR; PROTEIN MDM2; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; S PHASE KINASE ASSOCIATED PROTEIN 2; SMURF1 PROTEIN; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR NRF2; TRANSFORMING GROWTH FACTOR BETA; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE E3; UBIQUITIN PROTEIN LIGASE NEDD4; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CDKN1B PROTEIN, HUMAN; ENZYME INHIBITOR; PROTEASOME; S PHASE KINASE ASSOCIATED PROTEIN; SMURF1 PROTEIN, HUMAN; WWP1 PROTEIN, HUMAN; WWP2 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; GENE MUTATION; GENE OVEREXPRESSION; HEAD AND NECK CANCER; HUMAN; LC50; MOLECULARLY TARGETED THERAPY; MOUTH CANCER; MOUTH SQUAMOUS CELL CARCINOMA; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS REGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER STEM CELL; DRUG DESIGN; DRUG DEVELOPMENT; DRUG EFFECTS; ENZYMOLOGY; GENETICS; METABOLISM; MOUTH NEOPLASMS; PATHOLOGY; PROCEDURES; PROTEIN STABILITY; SIGNAL TRANSDUCTION; UBIQUITINATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DRUG DESIGN; DRUG DISCOVERY; ENZYME INHIBITORS; HUMANS; MOLECULAR TARGETED THERAPY; MOUTH NEOPLASMS; NEOPLASTIC STEM CELLS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN STABILITY; PROTEOLYSIS; S-PHASE KINASE-ASSOCIATED PROTEINS; SIGNAL TRANSDUCTION; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 84959360703     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/1568009616666151112122336     Document Type: Article

References (65)

1. Japan Society for Head and Neck Cancer Registry Committee: Report of head and neck cancer registry of Japan, Clinical statistics of patients, 2002. Oral cavity. Jpn. J. Head and Neck Cancer, 2006, 32, 15-34.
2. Nagata, T.; Masumoto, K.; Watanabe, Y.; Katou F. End-to-side anastomosis to the external jugular vein: preservation of external jugular vein blood flow. Br. J. Oral Maxillofac Surg., 2012, 50(2), 31-32.
3. Fuwa, N.; Kodaira, T.; Furutani, K.; Tachibana, H.; Nakamura, T. Treatment results of continuous intra-arterial CBDCA infusion chemotherapy in combination with radiation therapy for locally advanced tongue cancer. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod., 2008, 105(6), 714-719.
4. Ang, K.K.; Zhang, Q.; Rosenthal, DI.; Nguyen-Tan, P.F.; Sherman, E.J.; Weber, R.S.; Galvin, J.M.; Bonner, J.A.; Harris, J.; El-Naggar, A.K,; Gillison, M.L.; Jordan, R.C.; Konski, A.A.; Thorstad, W.L.; Trotti, A.; Beitler, J.J.; Garden, A.S.; Spanos, W.J.; Yom, S.S.; Axelrod, R.S. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or withoutcetuximab for stage III to IVhead and neck carcinoma: RTOG 0522. J. Clin. Oncol., 2014, 32(27), 2940-2950.
5. Hershko, A.; Ciechanover, A. The ubiquitin system. Annu. Rev. Biochem. 1998, 67, 425-479.
6. Weissman, A.M. Themes and variations on ubiquitylation. Nat. Rev. Mol. Cell Biol., 2001, 2, 169-178.
7. Nakayama, K.I.; Nakayama, K. Ubiquitin ligases: cell-cycle control and cancer. Nat. Rev. Cancer, 2006, 6, 369-381.
8. Tassone, P.; Old, M.; Teknos, T.N.; Pan, Q. p53-based therapeutics for head and neck squamous cell carcinoma. Oral Oncol., 2013, 49(8), 733-737.
9. Uchida, C.; Kitagawa, M. RING-, HECT-, and RBR-type E3 Ubiquitin Ligases: Involvement in Human Cancer. Curr. Cancer Drug Targets in press
10. Lim, K.P.; Sharifah, H.; Lau, S.H.; Teo, S.H.; Cheong, S.C. Alterations of the p14ARF-p53-MDM2 pathway in oral squamous cell carcinoma: MDM2 overexpression is a common event. Oncol. Rep., 2005, 14(4), 963-968.
11. Kresty, L.A.; Mallery, S.R.; Knobloch, T.J.; Song, H.; Lloyd, M.; Casto, B.C.; Weghorst, C.M. Alterations of p16(INK4a) and p14(ARF) in patients with severe oral epithelial dysplasia. Cancer Res., 2002, 62(18), 5295-5300.
12. Mondal, G.; Sengupta, S.; Panda, C.K.; Gollin, S.M.; Saunders, W.S.; Roychoudhury, S. Overexpression of Cdc20 leads to impairment of the spindle assembly checkpoint and aneuploidization in oral cancer. Carcinogenesis, 2007, 28(1), 81-92.
13. Uchida, F.; Uzawa, K.; Kasamatsu, A.; Takatori, H.; Sakamoto, Y.; Ogawara, K.; Shiiba, M.; Tanzawa, H.; Bukawa, H. Overexpression of cell cycle regulator CDCA3 promotes oral cancer progression by enhancing cell proliferation with prevention of G1 phase arrest. BMC Cancer, 2012, 12, 321.
14. Martinez, VD.; Vucic, E.A.; Thu, K.L.; Pikor, L.A.; Lam, S.; Lam, W.L. Disruption of KEAP1/CUL3/RBX1 E3-ubiquitin ligase complex components by multiple genetic mechanisms: Association with poor prognosis in head and neck cancer. Head Neck, 2015, 37(5), 727-734.
15. Hsieh, S.C.; Kuo, S.N.; Zheng, Y.H.; Tsai, M.H.; Lin, Y.S.; Lin, J.H. The E3 ubiquitin ligase SIAH2 is a prosurvival factor overexpressed in oral cancer. Anticancer Res., 2013, 33(11), 4965-4973.
16. Polyak, K.; Kato, J.Y.; Solomon, M.J.; Sherr, C.J.; Massague, J.; Roberts, J.M.; Koff, A. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev., 1994, 8(1), 9-22.
17. Polyak, K.; Lee, M.H.; Erdjument-Bromage, H.; Koff, A.; Roberts, J.M.; Tempst, P.; Massagué, J. Cloning of p27Kip1, a cyclindependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell, 1994, 78(1), 59-66.
18. Hirai, A.; Nakamura, S.; Noguchi, Y.; Yasuda, T.; Kitagawa, M.; Tatsuno, I.; Oeda, T.; Tahara, K.; Terano, T.; Narumiya, S.; Kohn, L.D.; Saito, Y. Geranylgeranylated rho small GTPase(s) are essential for the degradation of p27Kip1 and facilitate the progression from G1 to S phase in growth-stimulated rat FRTL-5 cells. J. Biol. Chem., 1997, 272(1), 13-6.
19. Kamura, T.; Hara, T.; Matsumoto, M.; Ishida, N.; Okumura, F.; Hatakeyama, S.; Yoshida, M.; Nakayama, K.; Nakayama, K.I. Cytoplasmic ubiquitin ligase KPC regulates proteolysis of p27(Kip1) at G1 phase. Nat. Cell Biol., 2004, 6(12), 1229-1235.
20. Leng, R.P.; Lin, Y.; Ma, W.; Wu, H.; Lemmers, B.; Chung, S.; Parant, J.M.; Lozano, G.; Hakem, R.; Benchimol, S. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell, 2003, 112(6), 779-791.
21. Hattori, T.; Isobe, T.; Abe, K.; Kikuchi, H.; Kitagawa, K.; Oda, T.; Uchida, C.; Kitagawa, M. Pirh2 promotes ubiquitin-dependent degradation of the cyclin-dependent kinase inhibitor p27Kip1. Cancer Res., 2007, 67(22), 10789-10795.
22. Tsvetkov, L.M.; Yeh, K.H.; Lee, S.J.; Sun, H.; Zhang, H. p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr. Biol., 1999, 9(12), 661-664.
23. Carrano, A.C.; Eytan, E.; Hershko, A.; Pagano, M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat. Cell Biol., 1999, 1(4), 193-199.
24. Ganoth, D.; Bornstein, G.; Ko, T.K.; Larsen, B.; Tyers, M.; Pagano, M.; Hershko, A. The cell-cycle regulatory protein Cks1 is required for SCF(Skp2)-mediated ubiquitinylation of p27. Nat. Cell Biol., 2001, 3(3), 321-324.
25. Nakayama, K.; Nagahama, H.; Minamishima, Y.A.; Matsumoto, M.; Nakamichi, I.; Kitagawa, K.; Shirane, M.; Tsunematsu, R.; Tsukiyama, T.; Ishida, N.; Kitagawa, M.; Nakayama, K. Hatakeyama, S. Targeted disruption of Skp2 results in accumulation of cyclin E and p27(Kip1), polyploidy and centrosome overduplication. EMBO J., 2000, 19(9), 2069-2081.
26. Spruck, C.; Strohmaier, H.; Watson, M.; Smith, A.P.; Ryan, A.; Krek, T.W.; Reed, S.I. A CDK-independent function of mammalian Cks1: targeting of SCF(Skp2) to the CDK inhibitor p27Kip1. Mol. Cell, 2001, 7(3), 639-650.
27. Yan, Y.; Zhang, X.; Legerski, R.J. Artemis interacts with the Cul4A-DDB1DDB2 ubiquitin E3 ligase and regulates degradation of the CDK inhibitor p27. Cell Cycle, 2011, 10(23), 4098-4109.
28. Inui, N.; Kitagawa, K.; Miwa, S.; Hattori, T.; Chida, K.; Nakamura, H.; Kitagawa, M. High expression of Cks1 in human non-small cell lung carcinomas. Biochem. Biophys. Res. Commun., 2003, 303(3), 978-984.
29. Chu, I.M.; Hengst, L.; Slingerland, J.M. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat. Rev. Cancer, 2008, 8(4), 253-267.
30. Hershko, D.D. Cyclin-dependent kinase inhibitor p27 as a prognostic biomarker and potential cancer therapeutic target. Future Oncol., 2010, 6(12), 1837-1847.
31. Frescas, D.; Pagano, M. Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. 7ancer, 2008, 8(6), 438-449.
32. Gstaiger, M.; Jordan, R.; Lim, M.; Catzavelos, C.; Mestan, J.; Slingerland, J.; Krek, W. Skp2 is oncogenic and overexpressed in human cancers. Proc. Natl. Acad. Sci. U S A, 2001, 98(9), 5043-5048.
33. Kudo, Y.; Takata, T.; Ogawa, I.; Zhao, M.; Sato, S.; Takekoshi, T.; Miyauchi, M.; Nikai, H. Reduced expression of p27(Kip1) correlates with an early stage of cancer invasion in oral squamous cell carcinoma. Cancer Lett., 2000, 151(2), 217-222.
34. Kitajima, S.; Kudo, Y.; Ogawa, I.; Bashir, T.; Kitagawa, M.; Miyauchi, M.; Pagano, M.; Takata, T. Role of Cks1 overexpression in oral squamous cell carcinomas: cooperation with Skp2 in promoting p27 degradation. Am. J. Pathol., 2004, 165(6), 2147-2155.
35. Shimada, M.; Kitagawa, K.; Dobashi, Y.; Isobe, T.; Hattori, T.; Uchida, C.; Abe, K.; Kotake, Y.; Oda, T.; Suzuki, H.; Hashimoto, K.; Kitagawa, M. High expression of Pirh2, an E3 ligase for p27, is associated with low expression of p27 and poor prognosis in head and neck cancers. Cancer Sci., 2009, 100(5), 866-872.
36. Yan, Y.; Akhter, S.; Zhang, X.; Legerski, R. The multifunctional SNM1 gene family: not just nucleases. Future Oncol., 2010, 6(6), 1015-1029.
37. Kravtsova-Ivantsiv, Y.; Shomer, I.; Cohen-Kaplan, V.; Snijder, B.; Superti-Furga, G.; Gonen, H.; Sommer, T.; Ziv, T.; Admon, A.; Naroditsky, I.; Jbara, M.; Brik, A.; Pikarsky, E.; Kwon, Y.T.; Doweck, I.; Ciechanover, A. KPC1-Mediated Ubiquitination and Proteasomal Processing of NF-κB1 p105 to p50 Restricts Tumor Growth. Cell, 2015, 161(2), 333-347.
38. Kudo, Y.; Kitajima, S.; Ogawa, I.; Kitagawa, M.; Miyauchi, M.; Takata, T. Small interfering RNA targeting of S phase kinaseinteracting protein 2 inhibits cell growth of oral cancer cells by inhibiting p27 degradation. Mol. Cancer Ther., 2005, 4(3), 471-476.
39. Yu, Z.K.; Gervais, J.L.; Zhang, H. Human CUL-1 associates with the SKP1/SKP2 complex and regulates p21(CIP1/WAF1) and cyclin D proteins. Proc. Natl. Acad. Sci. U S A, 1998, 95(19), 11324-11329.
40. Kamura, T.; Hara, T.; Kotoshiba, S.; Yada, M.; Ishida, N.; Imaki, H.; Hatakeyama, S.; Nakayama, K.; Nakayama, K.I. Degradation of p57Kip2 mediated by SCFSkp2-dependent ubiquitylation. Proc. Natl. Acad. Sci. U S A, 2003, 100(18), 10231-10236.
41. Tedesco, D.; Lukas, J.; Reed, S.I. The pRb-related protein p130 is regulated by phosphorylation-dependent proteolysis via the proteinubiquitin ligase SCF(Skp2). Genes Dev., 2002, 16(22), 2946-2957.
42. Hiramatsu, Y.; Kitagawa, K.; Suzuki, T.; Uchida, C.; Hattori, T.; Kikuchi, H.; Oda, T.; Hatakeyama, S.; Nakayama, K.I.; Yamamoto, T.; Konno, H.; Kitagawa, M. Degradation of Tob1 mediated by SCFSkp2-dependent ubiquitination. Cancer Res., 2006, 66(17), 8477-8483.
43. Huang, H.; Regan, K.M.; Wang, F.; Wang, D.; Smith, D.I.; van Deursen, J.M.; Tindall, D.J. Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc. Natl. Acad. Sci. U S A, 2005, 102(5), 1649-1654.
44. Song, M.S.; Song, S.J.; Kim, S.J.; Nakayama, K.; Nakayama, K.I.; Lim, D.S. Skp2 regulates the antiproliferative function of the tumor suppressor RASSF1A via ubiquitin-mediated degradation at the G1-S transition. Oncogene, 2008, 27(22), 3176-3185.
45. Imaki, H.; Nakayama, K.; Delehouzee, S.; Handa, H.; Kitagawa, M.; Kamura, T.; Nakayama, K.I. Cell cycle-dependent regulation of the Skp2 promoter by GA-binding protein. Cancer Res., 2003, 63(15), 4607-4613.
46. Huang, H.; Zhao, W.; Yang, D. Stat3 induces oncogenic Skp2 expression in human cervical carcinoma cells. Biochem. Biophys. Res. Commun., 2012, 418(1), 186-190.
47. Wei, Z.; Jiang, X.; Qiao, H.; Zhai, B.; Zhang, L.; Zhang, Q.; Wu, Y.; Jiang, H.; Sun, X. STAT3 interacts with Skp2/p27/p21 pathway to regulate the motility and invasion of gastric cancer cells. Cell Signal., 2013, 25(4), 931-938.
48. Barré, B.; Perkins, N.D. The Skp2 promoter integrates signaling through the NF-kappaB, p53, and Akt/GSK3beta pathways to regulate autophagy and apoptosis. Mol. Cell, 2010, 38(4), 524-538.
49. Suzuki, S.; Fukasawa, H.; Misaki, T.; Togawa, A.; Ohashi, N.; Kitagawa, K.; Kotake, Y.; Niida, H.; Hishida, A.; Yamamoto, T.; Kitagawa, M. Up-regulation of Cks1 and Skp2 with TNFα/NF-κB signaling in chronic progressive nephropathy. Genes Cells, 2011, 16(11), 1110-1120.
50. Chung, Y.K.; Chi-Hung, Or, R.; Lu, C.H.; Ouyang, W.T.; Yang, S.Y.; Chang, C.C. Sulforaphane down-regulates SKP2 to stabilize p27(KIP1) for inducing antiproliferation in human colon adenocarcinoma cells. J. Biosci. Bioeng., 2015, 119(1), 35-42.
51. Koo, K.H.; Kim, H.; Bae, Y.K.; Kim, K.; Park, B.K.; Lee, C.H.; Kim, Y.N. Salinomycin induces cell death via inactivation of Stat3 and downregulation of Skp2. Cell Death Dis., 2013, 4, e693.
52. Vosper, J.; Masuccio, A.; Kullmann, M.; Ploner, C.; Geley, S.; Hengst, L. Statin-induced depletion of geranylgeranyl pyrophosphate inhibits cell proliferation by a novel pathway of Skp2 degradation. Oncotarget, 2015, 6(5), 2889-2902.
53. Ooi, L.C.; Watanabe, N.; Futamura, Y.; Sulaiman, S.F.; Darah, I.; Osada, H. Identification of small molecule inhibitors of p27(Kip1) ubiquitination by high-throughput screening. Cancer Sci., 2013, 104(11), 1461-1467.
54. Ungermannova, D.; Lee, J.; Zhang, G.; Dallmann, H.G.; McHenry, C.S.; Liu, X. High-throughput screening AlphaScreen assay for identification of small-molecule inhibitors of ubiquitin E3 ligase SCFSkp2-Cks1. J. Biomol. Screen., 2013, 18(8), 910-920.
55. Wu, L.; Grigoryan, A.V.; Li, Y.; Hao, B.; Pagano, M.; Cardozo, T.J. Specific small molecule inhibitors of Skp2-mediated p27 degradation. Chem. Biol., 2012, 19(12), 1515-1524.
56. Chan, C.H.; Morrow, J.K.; Li C.F.; Gao, Y.; Jin, G.; Moten, A.; Stagg, L.J; Ladbury, J.E; Cai, Z.; Xu, D.; Logothetis, C.J.; Hung, M.C.; Zhang, S.; Lin, H.K.; Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell, 2013, 154(3), 556-568.
57. Yamagishi, Y.; Shoji, I.; Miyagawa, S.; Kawakami, T.; Katoh, T.; Goto, Y.; Suga, H. Natural product-like macrocyclic N-methyl-peptide inhibitors against a ubiquitin ligase uncovered from a ribosomeexpressed de novo library. Chem. Biol., 2011, 18(12), 1562-1570.
58. Zhi, X.; Chen, C. WWP1: a versatile ubiquitin E3 ligase in signaling and diseases. Cell. Mol. Life Sci., 2012, 69(9), 1425-1434.
59. Lin, J.H.; Hsieh, S.C.; Chen, J.N.; Tsai, M.H.; Chang, C.C. WWP1 gene is a potential molecular target of human oral cancer. Oral Surg. Oral Med. Oral Pathol. Oral Radiol., 2013, 116(2), 221-231.
60. Maddika, S.; Kavela, S.; Rani, N.; Palicharla, V.R.; Pokorny, J.L.; Sarkaria, J.N.; Chen, J. WWP2 is an E3 ubiquitin ligase for PTEN. Nat. Cell Biol., 2011, 13(6), 728-733.
61. Chen, W.; Jiang, X.; Luo, Z. WWP2: a multifunctional ubiquitin ligase gene. Pathol. Oncol. Res., 2014, 20(4), 799-803.
62. Fukumoto, C.; Nakashima, D.; Kasamatsu, A.; Unozawa, M.; Shida-Sakazume, T.; Higo, M.; Ogawara, K.; Yokoe, H.; Shiiba, M.; Tanzawa, H.; Uzawa, K. WWP2 is overexpressed in human oral cancer, determining tumor size and poor prognosis in patients: downregulation of WWP2 inhibits the AKT signaling and tumor growth in mice. Oncoscience, 2014, 1(12), 807-820.
63. Mund, T.; Lewis, M.J.; Maslen, S.; Pelham, H.R. Peptide and small molecule inhibitors of HECT-type ubiquitin ligases. Proc. Natl. Acad. Sci. U S A, 2014, 111(47), 16736-16741.
64. Massagué, J. TGFβ signalling in context. Nat. Rev. Mol. Cell. Biol., 2012, 13(10), 616-630
65. Khammanivong, A.; Gopalakrishnan, R.; Dickerson, E.B. SMURF1 silencing diminishes a CD44-high cancer stem cell-like population in head and neck squamous cell carcinoma. Mol. Cancer, 2014, 13, 260